Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases

SIMPLE SUMMARY: HER2-equivocal cases represent around 15% of breast carcinomas, and 20–40% of them are HER2-amplified. The distinction between HER2-amplified and non-amplified cases is of great importance for patient management, and in this study, we investigated the performance of STRAT4 (a RT-qPCR...

Descripción completa

Detalles Bibliográficos
Autores principales: Carretero-Barrio, Irene, Caniego-Casas, Tamara, Rosas, Marta, Sánchez, María Concepción, Martínez-Jáñez, Noelia, Chiva, Miguel, Sarrió, David, Moreno-Bueno, Gema, Palacios, José, Pérez-Mies, Belén
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046044/
https://www.ncbi.nlm.nih.gov/pubmed/36980575
http://dx.doi.org/10.3390/cancers15061688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046044/
https://www.ncbi.nlm.nih.gov/pubmed/36980575
http://dx.doi.org/10.3390/cancers15061688

Ejemplares similares